

Docket No. 220243US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2

IN RE APPLICATION OF: Stephen ARKINSTALL, et al.

SERIAL NO: New US PCT application based on PCT/IB00/01381

GAU:

FILED: Herewith

EXAMINER:

FOR: PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

*Norman F. Oblon*

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423



22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 10/01)

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO.  220243US0PCT		SERIAL NO. New US PCT application based on PCT/IB00/01381	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT  Stephen ARKINSTALL, et al.			
				FILING DATE  Herewith		GROUP	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	98 49188	11/05/98	WO		No	
	AP	0 330 065	08/30/89	EP		No	
	AQ						
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AR	R. Raja REDDY et al.: "New hypoglycemic agents--Part XVI: synthesis and evaluation of N3-aryl-N1'-4'-(3, 4-dihydro-3-oxo-2H-1, 4-benzoxazin-2-yl) acetic acid hydrazidosulfonylphenyl ureas/thioureas" INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 7, no. 3, pages 185-188 1998					
	AS	Xie XIAOLING et al.: "Crystal structure of JNK3: a kinase implicated in neuronal apoptosis" STRUCTURE, 6 (8), pages 983-991 1998					
	AT	Derek D. YANG et al.: "Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene" NATURE, 389 (6653), pages 865-870 1997					
	AU	Derek D. YANG et al.: "Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2" IMMUNITY, 9, pages 575-585 1998					
	AV	Kanaga SABAPATHY et al.: "JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development" CURRENT BIOLOGY, 3, pages 116-125 1999					
	AW	Yoshihiro KUMAGAE et al.: "Human c-Jun N-terminal kinase expression and activation in the nervous system" BRAIN RES. MOL. BRAIN RES., 67 (1), pages 10-17 1999				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner							
Date Considered							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							